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Background: Morton’s neuroma is a common foot condition affecting health-related quality of life. Though its
management frequently includes steroid injections, evidence of cost-effectiveness is sparse. So, we aimed to evaluate
whether steroid injection is cost-effective in treating Morton’s neuroma compared with anaesthetic injection alone.
Methods: We undertook incremental cost-effectiveness and cost-utility analyses from the perspective of the
National Health Service, alongside a patient-blinded pragmatic randomised trial in hospital-based orthopaedic
outpatient clinics in Edinburgh, UK. Of the original randomised sample of 131 participants with Morton’s neuroma
(including 67 controls), economic analysis focused on 109 (including 55 controls). Both groups received injections
guided by ultrasound. We estimated the incremental cost per point improvement in the area under the curve of
the Foot Health Thermometer (FHT-AUC) until three months after injection. We also conducted cost-utility analyses
using European Quality of life-5 Dimensions–3 Levels (EQ-5D-3L), enhanced by the Foot Health Thermometer (FHT), to
estimate utility and thus quality-adjusted life years (QALYs).
Results: The unit cost of an ultrasound-guided steroid injection was £149. Over the three months of follow-up, the mean
cost of National Health Service resources was £280 for intervention participants and £202 for control participants – a
difference of £79 [bootstrapped 95% confidence interval (CI): £18 to £152]. The corresponding estimated incremental
cost-effectiveness ratio was £32 per point improvement in the FHT-AUC (bootstrapped 95% CI: £7 to £100). If decision
makers value improvement of one point at £100 (the upper limit of this CI), there is 97.5% probability that steroid
injection is cost-effective. As EQ-5D-3L seems unresponsive to changes in foot health, we based secondary cost-utility
analysis on the FHT-enhanced EQ-5D. This estimated the corresponding incremental cost-effectiveness ratio as £6,400
per QALY. Over the recommended UK threshold, ranging from £20,000 to £30,000 per QALY, there is 80%-85%
probability that steroid injection is cost-effective.
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Conclusions: Steroid injections are effective and cost-effective in relieving foot pain measured by the FHT for
three months. However, cost-utility analysis was initially inconclusive because the EQ-5D-3L is less responsive than
the FHT to changes in foot health. By using the FHT to enhance the EQ-5D, we inferred that injections yield good
value in cost per QALY.
Trial registration: Current Controlled Trials ISRCTN13668166
Keywords: Morton’s neuroma, Interdigital plantar nerves, Methylprednisolone, Steroid injection, Foot health,
Cost-effectiveness analysis, Cost-utility analysis, Quality-adjusted life yearsBackground
Morton’s neuroma is the common descriptive term for a
benign neural swelling of one of the interdigital plantar
nerves. The condition most commonly affects the nerves
in the second and third interspaces and is more common
in middle-aged women [1,2]. Causal factors may include
high heeled or ill-fitting shoes, high impact athletic activ-
ities such as jogging and direct trauma [3,4]. Symptoms
from Morton’s neuroma may include paraesthesia, burn-
ing, numbness and pain [1,2,4]. The clinical and economic
significance of Morton’s neuroma is that prolonged disab-
ling foot pain can lead to limitations in daily activities and
sickness absence [2]. Treatment options include insertion
of insoles into footwear, steroid injections to manage foot
pain, and eventual surgery [5-7].
Steroid injections are common second-line interven-
tions but evidence of effectiveness and cost-effectiveness
is sparse [2]. This paper presents the economic findings
of a randomised trial of steroid injection in the treat-
ment of Morton’s neuroma [8]. This trial found that in
comparison with the control group, foot health in the
corticosteroid group was significantly better at one and
three months: at three months the mean difference was
14.1 points on the Foot Health Thermometer (95% con-
fidence interval: 5.5 to 22.8 points; p = 0.002). Cortico-
steroid injections also improved pain, function and
general health one and three months after injection. The
size of the neuroma on ultrasound did not significantly
influence the effect of treatment.
Since then there has been little change in clinical prac-
tice; steroid injections remain a second-line treatment
for Morton’s neuroma. The current systematic review
for the Cochrane Library [9] stresses the lack of clinical
evidence for this common condition. Hence, our primary
economic aim was to investigate the cost-effectiveness of
steroid injection compared with anaesthetic injection
alone in the treatment of Morton’s neuroma in reducing
foot pain over three months.
Methods
Study design and interventions
The economic evaluation took place alongside the trial
known as ‘Morton’s neuroma: Injected Steroids Effective?’(MortISE) [Registration: http://www.controlled-trials.com/
ISRCTN13668166], a patient-blinded pragmatic rando-
mised trial designed to compare the effectiveness of ster-
oid injections with anaesthetic injections in alleviating
pain and other effects of Morton’s neuroma [8]. The
trial included 131 patients with clinical symptoms of
Morton’s neuroma; their mean age was 53 years, and
111 were female. We randomised participants between
an intervention group receiving corticosteroid and an-
aesthetic injections [1 ml methylprednisolone (40 mg)
and 1 ml 2% lignocaine] and a control group receiving
anaesthetic alone (2 ml 1% lignocaine). We kept trial
participants blind to the type of injection they received.
Though we had intended also to keep the radiologist
blind, this proved impractical. Nevertheless the radiolo-
gist played no other part in the study [8].
Participants completed measures at baseline before
treatment and at follow-up clinics one and three months
after randomisation. We chose the interval of one month
to maximise clinical benefit and identify any adverse
events following injection; and that of three months to
estimate medium-term benefit. We collected the follow-
ing outcome data for the trial: neuroma size, foot pain
and disability by the Foot Health Thermometer (FHT)
and the Manchester Foot Pain and Disability Schedule,
pain by the Multidimensional Affect and Pain Survey
and health-related quality of life by the European Quality
of life-5 Dimensions–3 Levels (EQ-5D-3L). The primary
outcome was participants’ assessment of their foot
health by the FHT at three months after injection.
The Lothian Research Ethics Committee approved the
study. All participants provided written informed con-
sent before starting the study.
Economic evaluation
We conducted an economic evaluation three months after
randomisation of participants. Our aim was to evaluate
steroid injections for the treatment of Morton’s neur-
oma. To be comprehensive we addressed both cost-
effectiveness, which focuses on foot health, through the
FHT, and cost-utility, which addresses health-related qual-
ity of life. For the latter, the National Institute for Health
and Care Excellence (NICE) in the UK has recommended
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ure of health benefit for economic analysis as it allows
comparisons across different clinical conditions, unlike
condition-specific outcomes like the FHT [10].
As it is not easy to impute missing cost data, we based
economic analysis of this trial on a smaller sample than
the effectiveness analysis. Data for the costs of service
use were incomplete for 10 participants in the interven-
tion group and 12 participants in the control group,
though we had included 13 of them (5 intervention and
8 control) in effectiveness analyses. We had full eco-
nomic data and enough baseline and follow-up data to
impute QALYs and the area under the curve of the Foot
Health Thermometer (FHT-AUC) for 109 participants –
54 in the intervention group and 55 participants in the
control group. This represented 89% of the 122 partici-
pants in the main effectiveness analysis [8].
Measurement of costs
We examined costs from the perspective of the National
Health Service [11,12]. We estimated direct primary and
secondary care use from hospital records and partici-
pants’ self-reported client service receipt inventories [13]
at one and three months. Research resource constraints
prevented us from asking participants to complete client
service receipt inventories at baseline. At one and three
months the client service receipt inventories asked pa-
tients to recall all contacts with primary care, attendances
at emergency departments, and inpatient stays. From hos-
pital records we gathered data on steroid and anaesthetic
injections, outpatient visits, surgery, radiological imaging,Table 1 Unit cost (£) and source of health service use in the U
Health-care resource Unit
Primary care contacts, e.g. general practitioner, practice nurse. Consultation
PAMs, e.g. physiotherapist, chiropodist, consultant radiologist Consultation
Hospital outpatient clinic e.g. orthopaedic, opthalmologist Consultation
Hospital outpatient consultation with ultrasound scan Consultation
Hospital outpatient consultation with no ultrasound scan Consultation
Inpatient hospital stay Procedure
Accident and emergency Consultation
Steroid injection (1ml methylprednisolone (40 mg) and 1ml
2% Lignocaine)
Item
Anaesthetic injection (2ml of 1% Lignocaine) Item
Legend: Table 1 Unit cost of health service use in UK pounds sterling (£)a, with sou
PAMs: Professionals Allied to Medicines; BNF: British National Formulary.
aCost year 2011/12.
bNational Health Service costs including salary, employers’ costs, overheads and cap
cCosts extracted from Curtis and Netten [11] and Department of Health [10] have b
Service inflation indices from Curtis [12].
dFrom Curtis and Netten [11].
eFrom Department of Health [10].
fFrom BNF [13].and laboratory tests and investigations. We derived unit
costs of these service contacts in pounds Sterling from na-
tional sources [14,15] (Table 1).
We inflated these costs extracted from Department of
Health [14] and Curtis and Netten [15] from 2004–5 to
2011–2 using Hospital & Community Health Service in-
flation indices [16]. We obtained costs of steroid and an-
aesthetic drugs from the British National Formulary
version 52 [17] and inflated them to 2011–2 prices. Dur-
ing the three-month follow-up period, three participants
(two in the intervention group and one in the control
group) underwent surgical procedures for gastroentero-
logical and gynaecological conditions. As these inpatient
costs did not relate to foot health, we did not include
them in our analysis.
Measurement of effectiveness
Our primary analysis was a cost-effectiveness analysis
[10,18] using FHT-AUC, the area under the curve of
FHT scores, to measure the outcome of the trial. The
FHT is a validated visual analogue scale similar to the
EQ-5D-3L thermometer with 0 representing worst pos-
sible foot health and 100 best possible foot health [19].
We corrected all effects for differences in baseline, thus
improving the accuracy of estimated effects.
We undertook a cost-utility analysis using QALYs as
the measure of effect. We estimated participant utilities
by administering the EQ-5D-3L instrument [20] at base-
line, one month and three months; combined them
using the area under the curve method to calculate
QALY gains over the three month study period; andKa, b, c
Unit cost (£)a Details and source
12.30 to 84.86 Costed by professiond
12.30 to 51.65 Costed by professiond
103.31 to 110.69 Costed by specialtyd, e
with scan 145.74 Cost including costs of consultant
radiologist lasting 30mins, nurse lasting
30 minutes of client contact and an
ultrasound scand,e
with no scan 63.34 Cost of consultation lasting 30minse
154.96 Costed by proceduree
28.29 Costed by consultatione
3.74 Costed by BNF entryf
0.25 Costed by BNF entryf
rceb, c.
ital costs.
een inflated from 2004/05 to 2011/12 using Hospital & Community Health
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per QALY gain by dividing differences in cost by differ-
ence in QALYs and compared these with the thresholds
recommended by NICE in the UK [10]. We did not dis-
count costs or effects as the follow-up period was less
than one year.
To quantify the uncertainty around the estimated incre-
mental cost-effectiveness ratios, for both cost-effectiveness
and cost-utility analyses, we ran a simulation of 5000 non-
parametric bootstrapped iterations using MS Excel 2007.
We used these to estimate confidence intervals (CIs) for
incremental costs and incremental cost-effectiveness ra-
tios and to construct a cost-effectiveness plane – a scatter
plot of the joint distribution of incremental costs and ef-
fects – and a cost-effectiveness acceptability curve [21].
The cost-effectiveness acceptability curve displays the
probability that an intervention is more cost-effective than
the alternative across a range of thresholds of willingness
to pay for a QALY [22,23].
Sensitivity analyses
To assess how dependent on our original assumptions
our findings are, we undertook two forms of sensitivity
analysis. Firstly, we recognised that the MortISE trial
had adopted as its primary measure of benefit – the
FHT, a Patient-Reported Outcome Measure with evi-
dence of responsiveness to change [8]. In contrast, for
our cost-utility analysis alongside MortISE we chose as
primary measure of benefit – the EQ-5D-3L, a PROM
with a strong theoretical basis for its economic validity
[24,25]. However, as there are concerns that the use of
three-point scales by EQ-5D-3L reduces its responsive-
ness to change [26,27], we regressed the EQ-5D-3L data
from the MortISE participants as the dependent variable
on their FHT data as the independent variable, with allo-
cated treatment as the covariate. The resulting regres-
sion equation has two complementary functions: it
converts participants’ responses to the FHT into utilities
on the original EQ-5D-3L scale, and it uses the greater
discrimination achieved by the FHT to fill gaps in the
simplistic three-point scales that characterised the ori-
ginal EQ-5D-3L. Though the custodians of the EQ-5D-
3L have recently sought to improve responsiveness by
expanding scales to five points in the EQ-5D-5L [28],
the fact that we conceived MortISE before then stimu-
lated us to find another method of strengthening the
EQ-5D-3L, which we call the FHT-enhanced EQ-5D.
Secondly, we recognised that the costing of steroid in-
jections depended on the design of MortISE, which per-
formed ultrasound scans on all trial participants; in the
intervention group to guide the steroid injections, and in
the control group to assess the neuroma and need for
surgery. Though this design aimed to deliver best prac-
tice to the control group, it also had the explanatory aim[29] of equalising the ‘placebo effect’ between groups;
because both groups received ultrasound scans, we
could blind them to whether their injection contained
steroid or anaesthetic. For our second sensitivity analysis
we made the more pragmatic assumption [29] that con-
trol participants could attend the outpatient clinic for re-
view and injection without receiving an ultrasound scan.
If so, the unit cost of their hospital appointment, previ-
ously £145.74 including ultrasound scan, would fall to
£63.34 without ultrasound scan. We then added the unit
cost of anaesthetic injection (£0.25) to yield a total cost
of £63.59 for hospital appointment with anaesthetic in-
jection but no ultrasound scan.
Computing software
We analysed data in SPSS version 16.0 (SPSS Inc., Chicago
II, USA) and MS Excel 2007 (Microsoft Corporation,
Redmond, Washington DC, USA).
Results
Baseline demographic characteristics of study participants
Table 2 summarises the demographic characteristics of
participants in the intervention and control groups at
baseline. As in the main effectiveness paper [8], demo-
graphic variables were similar across intervention and
control groups.
Effectiveness
The effectiveness results for our economic sample of 109
participants were similar to those for the slightly larger
sample in the main effectiveness paper [8]: steroid injec-
tions significantly improved foot pain (by more than ten
points on the FHT) at both one month (p = 0.006) and
three months (p = 0.013); but had no significant effect on
health-related quality of life as measured by EQ-5D-3L.
Combining the results for each of the study time points
(baseline, one month and three months) into areas under
the curves and correcting for baseline, the intervention
group had significantly better FHT-AUC than the control
group, with a mean difference of 2.472 points (95% CI:
0.986 to 3.958; p = 0.001). However, the mean QALY gain
did not differ significantly between groups; the estimated
improvement in QALY from using steroid injections was
only 0.0038 (95% CI: −0.0146 to 0.0221, p = 0.68) [Table 3],
which is 1.4 quality-adjusted life days.
Frequency and cost of steroid and anaesthetic injections
We estimated the costs of an outpatient visit for
ultrasound-guided steroid injection as £149.48. This
comprised £3.74 for the steroid injection and £145.74
for the outpatient appointment, including 30 minutes of
consultant and nurse time, and an ultrasound scan. All
intervention participants received one ultrasound-guided
steroid injection at baseline.
Table 2 Baseline demographic characteristics of the
participating patients with Morton’s neuromaa
Control group
(n = 55)
Steroid group
(n = 54)
Gender
Male 9 (16%) 10 (19%)
Female 46 (84%) 44 (81%)
Age (year)
Mean (SD); range 52.6 (12.3); 26-76 54.3 (12.2); 28-79
Current smoker
Smoker 6 (11%) 6 (11%)
Ex-smoker 17 (31%) 17 (32%)
Non-smoker 32 (58%) 30 (56%)
Missing 0 (0%) 1 (2%)
Employment
In employment 34 (62%) 33 (61%)
Retired 12 (22%) 12 (22%)
Housework 7 (13%) 5 (9%)
Other 2 (4%) 3 (6%)
Missing 0 (0%) 1 (2%)
Education
Continued after the
minimum school
leaving ageb
Yes 31 (56%) 32 (60%)
No 24 (44%) 21 (39%)
Missing 0 (0%) 1 (2%)
Degree or equivalentb
Yes 18 (33%) 19 (35%)
No 37 (67%) 35 (65%)
Missing 0 (0%) 0 (0%)
Body Mass Index
(BMI) (kg/m2)
Mean (SD); range 27.7 (4.2); 21.3-40.7 27.7 (5.4); 21.1-52.1
aFigures are numbers (percentages) of the patients unless stated otherwise.
Percentages may not add to 100 due to rounding.
bThese two categories are not mutually exclusive.
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ultrasound-guided anaesthetic injection as £145.99. This
comprised £0.25 for the anaesthetic injection and the
same £145.74 for the outpatient appointment. All 55 con-
trol participants received one anaesthetic injection at
baseline but two also received a steroid injection at follow
up for the pain they were still experiencing (Table 4).
Frequency and cost of service use by participants
Tables 4 and 5 show the frequency and cost of contacts
with National Health Service primary and secondary
care by participants in intervention and control groups.
Table 5 shows mean costs of all services received byintervention and control participants over the three
month follow-up period. These included ultrasound-
guided injections, outpatient visits and primary care
consultations.
Table 5 shows mean cost differences and bootstrapped
95% CIs. The mean total cost per participant was £280.37
for the intervention group and £201.69 for the control
group. The difference in mean cost between the interven-
tion and control groups was £78.67 (bootstrapped 95% CI:
£18.25 to £152.34).
Primary cost–effectiveness analysis
The incremental cost–effectiveness ratio was £31.83 per
point improvement in FHT-AUC (bootstrapped 95% CI
from £6.79 to £99.94) – the result of dividing the differ-
ence in mean cost between intervention and control
groups (£280.37 - £201.69 = £78.68; Table 5) by the dif-
ference in mean FHT-AUC between the two groups
(14.748 - 12.276 = 2.472; Table 3).
Incorporating uncertainty
To assess uncertainty around incremental cost-effective-
ness ratio estimates, we ran 5,000 bootstrap replications;
Figure 1A shows the corresponding cost-effectiveness
plane. Most points (99.54%) fall within the North East
quadrant, where the intervention is both more costly
and more effective than the control group; 19 boot-
strapped replications (0.38%) fall in the South East quad-
rant (less costly, more effective) and the remaining four
bootstrapped replications (0.08%) fall in the North West
quadrant (more costly, less effective). Figure 1B shows
the probability that the intervention is cost-effective for
a range of cost thresholds. At the cost threshold of £100
for an improvement of one point in FHT-AUC, there is
97.5% probability that steroid injection is cost-effective.
Cost-utility analysis
The mean health gain, expressed as a difference in mean
QALYs between intervention and control groups over
the three month follow-up period, was 0.0038 years,
which is 1.4 quality-adjusted life days. We estimated the
corresponding incremental cost-effectiveness ratio as
£20,840 per QALY, by dividing the difference in mean
cost of £78.68 between intervention and control groups
(viz £280.37 - £201.69) by the difference in mean QALY
of 0.0038 between the two groups (viz 0.1511 - 0.1473).
We performed 5000 bootstrapped replications to gen-
erate a cost-effectiveness plane and a cost-utility accept-
ability curve. Figure 1C shows the cost-effectiveness
plane with 3307 points (66.14%) in the North East quad-
rant, 1686 (33.72%) in the North West quadrant, 2
(0.04%) in the South West quadrant and 5 (0.10%) in the
South East quadrant. Figure 1D is the corresponding
cost-utility acceptability curve. Because 33.72% of the
Table 3 Foot health thermometer scores and EQ-5D-3L utility index at baseline, 1 and 3 months
Outcome measurea (Control n = 55, Steroid n = 54)
Mean (SD) Mean adjusted for the baseline (SE) Estimated differenceb [95% CI]
significanceControl Steroid Control Steroid
EQ-5D-3L utility index
Baseline 0.5831 (0.2947) 0.5346 (0.3023) Not applicable Not applicable Not applicable
1 month 0.6213 (0.2523) 0.6129 (0.2717) 0.6178 (0.0351) 0.6164 (0.0354) −0.0014 (−0.0976, 0.1004) p = 0.98
3 months 0.5944 (0.2852) 0.6226 (0.2771) 0.5930 (0.0388) 0.6241 (0.0388) 0.0311 (−0.0780, 0.1403) p = 0.57
QALY 0.1510 (0.0522) 0.1506 (0.0511) 0.1473 (0.0062) 0.1511 (0.0068) 0.0038 (−0.0146, 0.0221) p = 0.68
Foot health thermometer scores
Baseline 48.17 (23.68) 45.23 (21.22) Not applicable Not applicable Not applicable
1 month 49.30 (24.21) 60.28 (22.01) 48.49 (3.07) 60.81 (3.10) 12.32 (3.66, 20.98) p = 0.006
3 months 53.06 (26.77) 64.26 (22.05) 52.77 (3.36) 64.69 (3.32) 11.92 (2.54, 21.29) p = 0.013
FHT-AUC 12.469 (5.061) 14.738 (4.038) 12.276 (0.504) 14.748 (0.556) 2.472 (0.986, 3.958) p = 0.001
aImputed where necessary.
bIn the final column, positive differences represent a better outcome for participants in the steroid group, and results in bold type are significant at 5% level.
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where the intervention is more costly and less effective:
this curve never reaches 70%; and estimation of an upper
limit for a two-sided 95% CI is not possible. Therefore,
only the bootstrapped one-sided 95% lower confidence
limit of £2,370 appears on the cost-effectiveness accept-
ability curve (Figure 1D). In the NICE threshold range
of £20,000 to £30,000 per QALY [10], the probability
that steroid injection is cost-effective lies between
49.7% and 54.9%.
Sensitivity analyses
Firstly, we replaced the EQ-5D by the FHT-enhanced
EQ-5D, and bootstrapped another 5000 replications to
produce a third pair of cost-effectiveness plane and cost-
effectiveness acceptability curve. Figure 1E shows 4553Table 4 Mean frequency of health service use over three mon
Count; mean, median, (min, max)
NHS Secondary Sector:
Injection:
Lignocaine only
Lignocaine & steroid
Outpatient consultation with ultrasound scan
Outpatient follow-up visits:
Return visits
Inpatient:
Inpatient hospital stay
Accident and emergency
NHS Primary Care Sector:
GP consultations
Other health care practitioner consultations
NHS: National Health Service.points (91.06%) in the North East quadrant, 431 (8.62%)
in the North West quadrant, 16 (0.32%) in the South
East quadrant, but none at all in the South West quad-
rant. Figure 1F presents the corresponding cost-utility
acceptability curve. Again, the curve never reaches 1 be-
cause more than 125 (2.5%) of bootstrapped estimates
fall in the North West quadrant, and the cost-
effectiveness acceptability curve shows only the lower
confidence limit of £1,380 (Figure 1F). The probability
that steroid injection is cost-effective now lies between
80.8% and 84.6% over the NICE threshold range of
£20,000 to £30,000 per QALY.
Secondly, we repeated the bootstrap and recalculated
the cost-effectiveness acceptability curve and incremental
cost-effectiveness ratio point estimate as if patients in the
control group had attended for an outpatient appointmentth follow-up period
Control (n = 55) Steroid (n = 54)
55; 1.00, 1.00 (1, 1) 0; 0.00, 0.00 (0, 0)
2; 0.04, 0.00 (0, 1) 54; 1.00, 1.00 (1, 1)
55; 1.00, 1.00 (1, 1) 54; 1.00, 1.00 (1, 1)
4; 0.07, 0.00 (0, 1) 6; 0.11, 0.00 (0, 1)
1; 0.02, 0.00 (0, 1) 23; 0.43, 0.00 (0, 6)
4; 0.07, 0.00 (0, 2) 5; 0.09, 0.00 (0, 2)
54; 0.98, 1.00 (0, 4) 73; 1.35, 1.00 (0, 12)
29; 0.53, 0.00 (0, 9) 35; 0.65, 0.00 (0, 9)
Table 5 Mean cost of health service use (£) over three month follow-up period
NHS Secondary Sector: Control n = 55
mean (SD) in £
Steroid n = 54
mean (SD) in £
Mean difference in £
(95% CI bootstrapped)
Injection:
Lignocaine only 0.25 (0.00) 0.00 (0.00) −0.25 (−)
Lignocaine & steroid 0.14 (0.71) 3.74 (0.00) 3.60 (−)
Outpatient consultation with ultrasound scan 145.74 (0.00) 145.74 (0.00) 0.00 (−)
Outpatient follow-up visits:
Return visits 4.61 (16.60) 7.04 (20.09) 2.43 (−4.52, 9.43)
Inpatient:
Inpatient hospital stay 2.82 (20.90) 66.00 (220.39) 63.19 (11.64, 126.32) *
Accident and emergency 2.06 (9.20) 2.62 (9.93) 0.56 (−3.05, 4.22)
Secondary care costs 155.61 (32.85) 225.14 (222.19) 69.53 (18.47, 148.49) *
NHS Primary Care Sector:
GP consultations 31.57 (35.77) 39.95 (56.52) 8.37 (−8.49, 26.92)
Other health care practitioner consultations 14.51 (43.06) 15.28 (40.55) 0.77 (−15.10, 16.58)
Primary care costs 46.09 (55.89) 55.23 (72.64) 9.14 (−14.68, 33.91)
Total costs 201.69 (67.74) 280.37 (246.74) 78.67 (18.25, 152.34) *
NHS: National Health Service.
*Difference is significant at 5% level.
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scenario the mean cost for the intervention group
remained unchanged, while the mean cost for the control
group fell from £201.69 (hospital outpatient visit with
ultrasound-guided injection) to £119.29 (hospital out-
patient visit with injection but no ultrasound guidance
scan). Thus, the incremental cost-effectiveness ratio rose
from £31.83 to £65.16 per point improvement on the
FHT-AUC (difference in mean total costs, £161.07, di-
vided by difference in mean FHT-AUC, 2.472), with a
bootstrapped 95% CI from £33.47 to £172.49. From the
cost-effectiveness acceptability curve, the probability that
steroid injection is cost-effective decreased to 85.2% at the
cost threshold of £100 per point improvement in FHT-
AUC (Figure 2B), compared with 97.5% in the primary
cost-effectiveness analysis (Figure 1B). Using QALYs, the
incremental cost-effectiveness ratio point estimate rose
from £20,840 to £42,660 per QALY; and the probability
that steroid injection is cost-effective decreased to be-
tween 33.5% and 43.4% (Figure 2D) in the NICE threshold
range of £20,000 to £30,000 per QALY, compared with
49.7% and 54.9% in Figure 1D.
Substituting the FHT-enhanced EQ-5D for the ori-
ginal EQ-5D-3L again brings the incremental cost-
effectiveness ratio below the lower UK threshold of
£20,000, specifically to £13,800; and increases the prob-
ability of cost-effectiveness to 67.4% at the lower
threshold of £20,000 and 77.2% at the higher threshold
of £30,000 (Figure 2F).Discussion
The MortISE trial with 131 participants found that foot
health in the steroid group was significantly better than
in the control group: the mean difference in the patient-
centered Foot Health Thermometer (FHT) at 3 months
was 14.1 scale points (95% CI: 5.5 to 22.8 points; p =
0.002) [8]. In the reduced sample of 109 participants for
whom we had enough data for economic analysis, the
mean difference fell to 11.9 scale points (95% CI: 2.5 to
21.3 points; p = 0.013). When divided by the correspond-
ing standard deviations of the baseline FHT scores, these
differences yield ‘effect sizes’ of 0.62 and 0.53 respect-
ively. Effect sizes greater than 0.5 are generally regarded
as moderate and therefore worthwhile [30].
This economic evaluation supports and extends the
findings from our clinical trial. If decision makers value
an improvement of one point on the FHT over one year
at £100, the upper confidence limit of the corresponding
incremental cost-effectiveness ratio, then the use of
ultrasound-guided steroid injection to alleviate foot pain
from Morton’s neuroma is cost-effective with a probability
of 97.5%; and a cost per point improvement on the FHT
of only £32. In contrast, our secondary cost-utility analysis
generated a cost per QALY of £20,840 and probability of
cost-effectiveness little more than 50% across the recom-
mended UK threshold, which ranges from £20,000 to
£30,000 [10]. Though this estimated incremental cost-
effectiveness ratio is similar to that for using steroid treat-
ment to manage sciatica [31], the discrepancy between
(A) (B)
(C) (D)
(E) (F)
Figure 1 Cost-effectiveness planes with 5,000 bootstrapped incremental cost-effectiveness ratio estimates for MortISE economic evaluation.
Cost-effectiveness planes for Foot Health Thermometer (A), QALY (C) and FHT-enhanced QALY – 1st sensitivity analysis (E); and cost-effectiveness
acceptability curves at three months for Foot Health Thermometer (B), QALY (D) and FHT-enhanced QALY – 1st sensitivity analysis (F).
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(A) (B)
(C) (D)
(E) (F)
Figure 2 Sensitivity analysis: cost-effectiveness planes with 5,000 bootstrapped incremental cost-effectiveness ratio estimates for
MortISE economic evaluation. 2nd sensitivity analysis: cost-effectiveness planes for Foot Health Thermometer (A), QALY (C) and FHT-enhanced
QALY (E); and cost-effectiveness acceptability curves at three months for Foot Health Thermometer (B), QALY (D) and FHT-enhanced QALY (F).
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to the danger that the latter had suffered from the known
lack of responsiveness of the original EQ-5D [26,27].
We addressed this discrepancy by a sensitivity analysis
that replaced the original EQ-5D by an enhanced version
combining the economic validity of the EQ-5D with the
greater responsiveness of the FHT. This reduced the in-
cremental cost-effectiveness ratio to £6,400, well below
the lower UK threshold of £20,000. This analysis also in-
creased, to more than 80%, the probability that steroid
injections for Morton’s neuroma are cost-effective. We
believe this analysis, nominally secondary, has bridged
the gap between our positive findings about effectiveness
[8] and our initially negative findings about cost-
effectiveness. The strength of the association in our data
between EQ-5D and FHT has convinced us that the
strong evidence about effectiveness from the condition-
specific FHT translates into sufficient evidence about
cost-effectiveness from the enhanced EQ-5D.
Our second sensitivity analysis indicates that, if control
participants attend outpatient clinics and receive injec-
tion but no ultrasound scan, the incremental cost-
effectiveness ratio would rise from £32 to £65 per point
improvement in FHT-AUC. This is still below our illus-
trative cost ceiling of £100. However, the cost per QALY
would rise to £42,660, well above the higher UK thresh-
old of £30,000.
As we are reporting findings after three months, we
do not know whether the improvement in foot health
was maintained, increased or reduced. As we explained
in the main effectiveness paper of the MortISE trial [8],
it is not appropriate to extrapolate effectiveness or
cost-effectiveness findings beyond the period of data
collection.
We believe this is the first cost-effectiveness study of
steroid injections to alleviate pain from Morton’s neur-
oma. As we cannot compare our findings with other
cost-effectiveness analyses in Morton’s neuroma, we
have compared them with steroid treatment in managing
sciatica.
The conclusions from this trial suffer from follow-up
of only three months and our focus on direct costs to
the National Health Service, rather than patient-borne
costs. Though we would have preferred longer follow-up
to assess the effect of steroid injection on subsequent
surgical rates, the ethical committee insisted that we
offer the intervention to participants in the control
group after three months [8].
Though we asked participants about their own re-
source use, the self-reported client service receipt inven-
tory is an accepted method of data collection when the
recall period is only three months [32]. Furthermore, it
facilitates the collection of data from many sources, as
in this trial, where we are interested in both primary andsecondary healthcare sectors. Hence, we see self- report-
ing in these patients as efficient use of research re-
sources. For participants referred to private hospitals, we
tried to obtain data on the resulting costs, but failed be-
cause those hospitals would not give us access to com-
mercially sensitive data.
This trial has shown that steroid injection is effective
and cost-effective for the National Health Service in
treating Morton’s neuroma in the short term. Any fur-
ther trial of the management of Morton’s neuroma
should plan a longer follow-up period. It could also ex-
plore the effectiveness and cost-effectiveness of combi-
nations of treatments, including the provision of insoles,
analgesia and physiotherapy as well as steroid injection.
It could also adopt a wider perspective to include
patient-borne costs of attending hospital for treatment
and of self-management of this condition.
Conclusions
Steroid injections are effective and cost-effective in reliev-
ing foot pain measured by the Foot Health Thermometer
(FHT) for three months. However cost-utility analysis was
initially inconclusive because the EQ-5D-3L is less respon-
sive than the FHT to changes in foot health. By using the
FHT to enhance the EQ-5D, we inferred that steroid in-
jections yield good value in cost per QALY.
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